sofinnova ventures home team portfolio about news contact healthquest capital sofinnova partners investor portal partners for development equity in biotech sofinnova ventures news september   heather behanna to speak at world antimicrobial resistance congress  may   sofinnova announces the addition of industry leader alan colowick md mph to its partnership april   jim healy to speak at cancer advance boston february   charlotte shropshire to speak at superreturn us west october   sofinnova steps up october   sofinnova raises  million for oversubscribed fund x june   jim healy to speak at bio on market  political pressures portfolio news june   art krieg comes down from the mountain with a m round for checkmate pharmaceuticals march   virtual biotech antiva sets out on a big rd quest armed with a m round for an hpv therapy march   bioclin therapeutics inc raises  million in series b financing led by sofinnova ventures and ysios capital january   obseva sa announces pricing of initial public offering january   obseva expands leadership team and board of directors with industry veterans december   novartis bolsters innovative dermatology portfolio through acquisition of ziarco group limited november   galera therapeutics receives m from sofinnova ventures november   galera therapeutics expands series b to  million contact menlo park  sand hill road building  suite  menlo park ca  telephone   san diego  prospect street ocean level   la jolla ca  telephone   for inquiries please email infosofinnovacom for information about our sister firm sofinnova partners based in paris france please visit wwwsofinnovafr   sofinnova ventures inc active investments portfolio  sofinnova ventures home team portfolio about news contact healthquest capital sofinnova partners investor portal active investments selected realized investments remaining it investments active investments aclaris therapeutics specialty pharmaceutical dermatology company focused on the development of novel dermatologic therapies nasdaq acrs aerie pharmaceuticals clinicalstage biotechnology company dedicated to the discovery and development of novel treatments for glaucoma nasdaq aeri alimera sciences specializes in the research development and commercialization of prescription ophthalmic pharmaceuticals nasdaq alim amarin focused on improving the treatment of cardiovascular disease the company’s cardiovascular programs capitalize on its expertise in the field of lipid science and the known therapeutic benefits of essential fatty acids in treating cardiovascular disease nasdaq amrn anthera pharmaceuticals focused on developing and commercializing products to treat serious diseases associated with inflammation including cardiovascular and autoimmune diseases nasdaq anth antiva develop creatively designed therapeutics that dramatically improve health outcomes for patients suffering from diseases caused by hpv and other viruses ascendis pharma ascendis pharma develops differentiated prodrug versions of highvalue protein drugs such as growth hormone nasdaq asnd atyr pharma focused on the discovery and clinical development of innovative medicines for patients suffering from severe rare diseases using its knowledge of physiocrine biology a newly discovered set of physiological modulators nasdaq life audentes therapeutics committed to the development and commercialization of innovative new treatments for people with serious rare diseases through the application of gene therapy technology nasdaq bold auris medical prevention or treatment of inner ear disorders for acute inner ear tinnitus and for acute inner ear hearing loss nasdaq ears bioclin therapeutics our strategy is to develop biologics for medical conditions where there has been no approved or satisfactory therapy our lead product b is a human antibody targeting fgfr fibroblast growth factor receptor  being developed as a treatment for metastatic bladder cancer and achondroplasia dwarfism catalyst biosciences creating novel catalytic biopharmaceutical products based on engineered human proteases checkmate pharmacueticals developing novel approach to specifically activating the immune system to recognize and ultimately destroy tumor cells chiasma latestage biotech developing an oral drug candidate for acromegaly nasdaq chma coherus biosciences a leading developer of highquality therapeutics with a robust pipeline of biosimilar products nasdaq chrs dauntless pharmaceuticals biopharmaceutical company focused on the development of specialty drugs edge therapuetics develops commercialize novel hospitalbased therapies capable of transforming treatment paradigms in the management of acute lifethreatening neurological conditions nasdaq edge first aid shot therapy focused on the development and commercialization of a comprehensive portfolio of otc pharmaceutical products in liquid shot format galera therapeutics galera therapeutics is a private clinicalstage biotech company focused on the development of breakthrough drugs targeting the oxygen metabolic pathways histogenics combining cell therapy and tissue engineering technologies to develop highly innovative products for tissue repair and regeneration nasdaq hsgx hyperion therapeutics focused on the development of treatments that address critical unmet needs in the areas of gastroenterology and hepatology nadsaq hptx innocoll developing and manufacturing a range of pharmaceutical products and medical devices using its proprietary collagenbased technologies nasdaq innl merus clinicalstage immunooncology company developing innovative bispecific antibody therapeutics to treat and potentially cure cancer patients mirna therapeutics developing tumor suppressor micrornas mirnas to kill cancer cells by regaining control over multiple oncogenic pathways nasdaq mirn natera develops and commercializes noninvasive methods for analyzing dna nucana developing and commercialising novel anticancer medicines including next generation nucleotide prodrugs obseva dedicated to the development of innovative drugs for women’s reproductive medicine including preterm labor ocera focused on the development of drugs to treat a broad range of gastrointestinal and liver diseases nasdaq ocrx ophthotech corporation specializing in the development of novel therapeutics to treat diseases of the eye nasdaq opht principia biopharma focused on discovering and developing firstinclass small molecule drugs within the fields of autoimmune disease and oncology that are potent and safe prothena advancing and developing novel antibodies for broad range of diseases involving protein misfolding or cell adhesion including amyloidosis nasdaq prta spark therapeutics focused on developing curative onetime gene therapy products including lead gene therapy candidate for rperelated blindness nasdaq once versartis developing therapeutics for the treatment of endocrine disorders including human growth hormones nasdaq vsar ziarco ziarco is a private clinical stage biotechnology company developing products to treat chronic inflammatory diseases with a focus on inflammatory skin disorders in particular atopic dermatitis and psoriasis these diseases impact the wellbeing of millions of children and adults globally by severely reducing quality of life zs pharma focused on the treatment of kidney and liver diseases including hyperkalemia nasdaq zsph   sofinnova ventures inc active investments portfolio news june  art krieg comes down from the mountain with a m round for checkmate pharmaceuticals march  virtual biotech antiva sets out on a big rd quest armed with a m round for an hpv therapy march  bioclin therapeutics inc raises  million in series b financing led by sofinnova ventures and ysios capital january  obseva sa announces pricing of initial public offering january  obseva expands leadership team and board of directors with industry veterans december  novartis bolsters innovative dermatology portfolio through acquisition of ziarco group limited november  galera therapeutics receives m from sofinnova ventures november  galera therapeutics expands series b to  million july  dauntless takes flight with new business model for starting biotechs contact  sofinnova ventures home team portfolio about news contact healthquest capital sofinnova partners investor portal contact information menlo park  sand hill road building  suite  menlo park ca  usa work telephone   fax fax   infosofinnovacom san diego  prospect street ocean level   la jolla ca  usa work telephone   fax fax   infosofinnovacom   sofinnova ventures inc team  sofinnova ventures home team portfolio about news contact healthquest capital sofinnova partners investor portal james healy mike powell anand mehra alan colowick lars ekman david kabakoff daniel welch nathalie auber heather behanna sarah bhagat eric delbridge tommy nguyen goro takeda alain azan hooman shahlavi james brody charlotte shropshire paul arata alfred yue alex chan kenny joo tina giangiacomoyogya tiffany davis jenn symmons josie kastelic rachel preston frances benson lesley weber alex dulnev team james healy general partner mike powell general partner anand mehra general partner alan colowick partner lars ekman executive partner private equity david kabakoff executive partner private equity daniel welch executive partner private equity nathalie auber partner and cfo heather behanna principal private equity sarah bhagat associate private equity eric delbridge portfolio manager public equity tommy nguyen associate portfolio manager public equity goro takeda venture partner alain azan founding partner hooman shahlavi partner  general counsel james brody chief compliance officer charlotte shropshire investor relations  marketing paul arata hr  administration alfred yue vice president finance alex chan senior accountant kenny joo financial analyst tina giangiacomoyogya events coordinator tiffany davis office manager  executive assistant jenn symmons executive assistant josie kastelic executive assistant rachel preston office assistant frances benson administrative receptionist lesley weber san diego office manager  executive assistant alex dulnev it manager   sofinnova ventures inc about  sofinnova ventures home team portfolio about news contact healthquest capital sofinnova partners investor portal about us founded in  sofinnova is a clinicalstage biopharmaceutical venture capital firm with approximately b under management we are a passionate and committed team of mds and phds that deploy human and financial capital to improve the lives of patients through science our mission is to provide industry leading venture returns by delivering transformative medicines to patients we live our mission to deliver outstanding results for those we serve – patients entrepreneurs and the people and organizations that entrust us with their capital sofinnova specializes in clinical and late preclinical investments in biopharmaceutical products we actively partner with entrepreneurs across all stages of company formation including securing initial funding building successful management teams forming impactful corporate alliances and navigating the ma acquisition or ipos process we seek to build world class companies that aspire to dramatically improve the current state of medical care today and ultimately the lives of patients the history of sofinnova ventures sofinnova represents decades of active venture investing in silicon valley  our original french parent firm sofinnova sa was founded in paris in  and has the distinction of being one of the earliest venture capital firms in europe sofinnova moved into the us in  to build a transatlantic useu connection  jean deleage was the first president and founder of the us arm of sofinnova  sofinnova sa had great success in the us being an early investor in stellar companies such as tandem computers and genentech sofinnova sa initiated a new family of us venture funds in  aptly described as sofinnova venture partners i ii iii and more sofinnova invested the first three of these funds in primarily information technology and was known as a ‘boutique french vc firm’ until the late s each of these us sofinnova funds were raised invested and managed independently from the funds managed and invested by sofinnova in paris and both partnerships continued to be owned by sofinnova sa until the late s in  sofinnova restructured into two independent management firms sofinnova partners in paris and sofinnova ventures in san francisco each firm became an independent venture capital firm with independent funds investment strategies and partnerships it was the vision of the partners in  that each of the firms should be owned by the partners doing the investing allowing the carried interest profits to remain with the investing professionals aligning their interests with the limited partners who invest in the funds  that said the sister firms share deal flow expertise and due diligence information as well as invest together selectively on a casebycase basis since  sofinnova ventures has been almost exclusively life science focused and its two most recent funds svp viii and svp ix are exclusively life science   their biotech focus is on drug development mostly later stage with an emphasis on specialty pharma orphan drugs and rare diseases  key therapeutic areas include oncology respiratory neuro dermatology and areas where a primary sales force is not needed sofinnova ventures has a long track record of working closely with entrepreneurs to build leading biotech companies a more detailed history of the global sofinnova organization can be found here   sofinnova ventures inc weblp login menlo park login to weblp v please provide the following information forgot password need support emailfinancesofinnovacom copyright  efront    all rights reserved open source licenses copyright  efront    all rights reserved this product includes the following libraries which are covered by the mit license jquery jquery ui jplayer dropdown check list jquery mouse wheel html placeholder jquery plugin simplemodal jquery validation plugin jscrollpane jquery color picker devageservicemodel pdfsharp in public domain json covered by the mspl license yahoo yui compressor for net expression tree serializer ioniczip covered by microsoft limited public license report viewer sync framework covered by apache  license lognet castlecore castledynamicproxy covered by gnu lesser general public license nhibernate object relational mapper iesicollections nhibernatelinq nhibernatebytecodecastle covered by code project open license compactformatterplus adohelper binary serializerdeserialzer covered by bsd license antlr fluent nhibernate covered by bsd clause license msbuild community tasks covered by zliblibpng license nunit news  sofinnova ventures home team portfolio about news contact healthquest capital sofinnova partners investor portal rss feed portfolio news june   art krieg comes down from the mountain with a m round for checkmate pharmaceuticals march   virtual biotech antiva sets out on a big rd quest armed with a m round for an hpv therapy march   bioclin therapeutics inc raises  million in series b financing led by sofinnova ventures and ysios capital january   obseva sa announces pricing of initial public offering january   obseva expands leadership team and board of directors with industry veterans december   novartis bolsters innovative dermatology portfolio through acquisition of ziarco group limited november   galera therapeutics receives m from sofinnova ventures november   galera therapeutics expands series b to  million july   dauntless takes flight with new business model for starting biotechs july   audentes announces ipo july   auris medical keyzilen granted fast track designation by fda july   coherus announces positive topline results june   auris makes front page on bio world auris gives assent may   coherus announces proposed public offering of common stock may   merus announces ipo past articles    sofinnova ventures inc sofinnova news september   heather behanna to speak at world antimicrobial resistance congress  may   sofinnova announces the addition of industry leader alan colowick md mph to its partnership april   jim healy to speak at cancer advance boston february   charlotte shropshire to speak at superreturn us west october   sofinnova steps up past articles  events december  jay shepard janssen labs annual trends in financing holiday industry panel december  mike powell acceleration  panel exits for life science companies october  sofinnova japan biopharma partnering conference september  mike powell  california biotech ceo conference “funding companies today” august  jim healy brookings expert workshop on limited use for drugs developed in an expedited manner to meet an unmet medical need media contact charlotte shropshire director of investor relations and marketing sofinnova ventures charlottesofinnovacom   sofinnova venture partners vi lp private company information  bloomberg july    pm et capital markets company overview of sofinnova venture partners vi lp snapshot people company overview sofinnova venture partners specializes in venture capital investments in early stage information technology and life sciences companies it invests in infrastructure for internet and telecommunications digital media and productoriented life sciences the fund typically focuses on seedstage and first institutional round investments but it occasionally invests in intermediate and laterstage startup companies it seeks to invest  per cent of its capital in the united states with the remaining  per cent invested in european developed markets the fund’s it investing is heavily focused on the san francisco bay area while the life science investments covers san diego san francisco an sofinnova venture partners specializes in venture capital investments in early stage information technology and life sciences companies it invests in infrastructure for internet and telecommunications digital media and productoriented life sciences the fund typically focuses on seedstage and first institutional round investments but it occasionally invests in intermediate and laterstage startup companies it seeks to invest  per cent of its capital in the united states with the remaining  per cent invested in european developed markets the fund’s it investing is heavily focused on the san francisco bay area while the life science investments covers san diego san francisco and seattle it typically invests between  million and  million in each company detailed description  sand hill roadbuilding suite menlo park ca united statesfounded in  phone  fax  key executives for sofinnova venture partners vi lp dr james i healy md phd general partner managing partner and partner age  mr alain l azan founding partner dr michael f powell phd general partner and managing general partner age  compensation as of fiscal year  similar private companies by industry company name region visory llc united states  road partners llc united states t partners llc united states jumpcom inc united states  ontario inc united states recent private companies transactions typedate target no transactions available in the past  months request profile update   the information and data displayed in this profile are created and managed by sp global market intelligence a division of sp global bloombergcom does not create or control the content for inquiries please contact sp global market intelligence directly by clicking here stock quotes market data is delayed at least  minutes company lookup most searched private companies company name geographic region lawyers committee for civil rights under law united states nyc inc united states bertelsmann ag europe the advertising council inc united states rush university united states sponsored financial commentaries sponsored links browse companies a b c d e f g h i j k l m n o p q r s t u v w x y z              request profile update only a company representative may request an update for the company profile documentation will be required to contact sofinnova venture partners vi lp please visit  company data is provided by sp global market intelligence please use this form to report any data issues information missing  please enter your information in the following fields company name your name your email address your phone number type of data overview executives key developments similar companies transactions update needed all data changes require verification from public sources please include the correct value or values and a source where we can verify cancel submit your requested update has been submitted our data partners will research the update request and update the information on this page if necessary research and followup could take several weeks if you have questions you can contact them at bwwebmasterbusinessweekcom close sofinnova  wikipedia sofinnova from wikipedia the free encyclopedia jump to navigation search sofinnova is the name shared by two venture capital firms sofinnova ventures and sofinnova partners the name sofinnova is believed to be a contraction of the french société de financement de l’innovation or innovation venture capital company both firms trace their roots back to sofinnova sa an investment institution founded in paris in  the two firms have raised b since inception and shared a similar investment strategy of investing in the life science and technology sectors the two sister firms distinguish themselves on the basis of their target geographies and have been fully independent since  sofinnova ventures has offices in menlo park ca and san diego ca and focuses largely on us biotech investments with  allocation for europe sofinnova partners is based in paris and focuses primarily on european biotech and cleantech investments with a similar reciprocal allocation for the us sofinnova ventures and sofinnova partners have had historically some of the same limited partners and have coinvested together in selected companies including flamel cerep genset actelion preglem movetis ascendis obseva auris and nucana both firms work together in a collegial way to exchange information and due diligence in each others respective geographies the firms do not have an obligation to show each other deals or to coinvest but historically have coinvested together in  of their collective investments sofinnova ventures usaedit sofinnova ventures type private industry private equity founded  headquarters menlo park ca united states key people jim healy md phd mike powell phd anand mehra md lars ekman md david kabakoff phd dan welch cory freeland phd tommy nguyen md phd nathalie auber hooman shalavi charlotte shropshire alain azan retired jean deleage deceased products venture capital total assets b number of employees  website wwwsofinnovacom sofinnova ventures is an independent venture capital firm based in menlo park with b capital under management investmentsedit sofinnova ventures has been an active venture investor investing in some wellknown venture investments of the period sofinnova invested in collagen aesthetics biogen genentech tandon tandem computers and printonix tumbleweed and phonecom sofinnova ventures funded several of these as startups that developed into large international companies more recently sofinnova ventures has backed companies including millennium pharmaceuticals kosan biosciences actelion intermune seattle genetics cotherix threshold pharmaceuticals prestwick preglem movetis intellikine amarin corporation salveo and labrys the san francisco office of sofinnova ventures was often remembered for having an original  ft mosasaurus in the office of one of the managing partners mike powell sofinnova ventures closed their san francisco office in  and combined their bay area offices into a single office on sand hill road in menlo park sofinnova ventures has raised several venture capital funds see table the earlier funds svp i through v were predominantly information technology it wherein the later funds were predominantly life science focused svp viii and ix were exclusively life science only with emphasis on phase  and  drug development svp iv was sofinnova ventures initial fund after the reorganization of sofinnova in  each of the funds from svp v through svp ix exceeded the target raise and closed at the maximum amount as allowed by the limited partner agreements year amount fund  m sofinnova venture partners i  m sofinnova venture partners ii  m sofinnova venture partners iii  m sofinnova venture partners iv  m sofinnova venture partners v  m sofinnova venture partners vi  m sofinnova venture partners vii  m sofinnova venture partners viii  m sofinnova venture partners ix source private equity intelligence and sofinnova sofinnova partners franceedit sofinnova partners type private industry private equity founded  headquarters paris france key people denis lucquin antoine papiernik rafaele tordjman graziano seghezzi henrijette richter monique saulnier jeanbernard schmidt retired jean deleage deceased products venture capital total assets € billion website wwwsofinnovafr sofinnova partners is an independent venture capital firm based in paris with approximately € billion of capital the firm invests in early stage companies and corporate spinoffs in clean technology and life science sofinnova has financed more than  companies in europe since inception  of which more than  have successfully completed an initial public offering and more than  have been acquired by strategic buyers investmentsedit following the separation of the two firms sofinnova partners completed fundraising for its third private equity fund sofinnova capital iii with €m among the investments in this fund are innate maximiles and novuspharma sofinnovas fourth fund which raised €m of capital made sofinnova one of the largest venture firms in europe at the time in  sofinnova partners was named “fund of the year” by private equity international and “vc techno house of the year ” by the european venture capital journal evcj which described sofinnovas fundraising as the “fundraising of the year ” this fund invested in a number of companies including taptu sofinnova partners has raised several venture capital funds see table year amount fund  €m sofinnova capital i  €m sofinnova capital ii  €m sofinnova capital iii  €m sofinnova capital iv  €m sofinnova capital v  €m sofinnova capital vi  €m sofinnova capital vii  €m sofinnova capital viii source private equity intelligence and sofinnova historyedit history of private equity and venture capital early history origins of modern private equity the s leveraged buyout boom the s leveraged buyout and the venture capital bubble the s dotcom bubble to the credit crunch v t e s the founding of sofinnovaedit   sofinnova was founded with the backing of several french financial institutions most notably crédit national and was notable at the time for creating the first american style venture capital firm in france peter brooke the founder of ta associates was a board member of sofinnova sa in its early years sofinnova sa quickly established a presence in the european market through the formation of sofinnova partners in paris sofinnova sa owned this firm from  until    sofinnova became the first european venture company to enter the us market launching its us affiliate sofinnova inc sofinnova ventures sofinnova cofounder jean deleage who would later cofound us venture firm burr egan deleage  co was appointed the head of the us operation sofinnovas us business gained attention for its role as an early backer of tandem computers and genentech in the early s   sofinnova cofounder jean deleage established the american subsidiary of sofinnova called sofinnova inc in san francisco which eventually became sofinnova ventures deleage departed sofinnova in  to cofound another venture capital firm burr egan deleage  co in  working with deleage sofinnova developed a partnership with burr egan deleage  co and ultimately other us firms jeanbernard schmidt who would later serve as chairman of sofinnova was named the head of us operations of sofinnova inc s the early growth of sofinnovaedit   sofinnova completed an initial public offering with a listing on the paris stock exchange   alain azan moved to san francisco to take over management of sofinnova ventures replacing jeanbernard schmidt schmidt would be named chairman of sofinnova retaining that position through  sofinnova ventures completed fundraising for svp i which was an private equity fund originally intended to invest in european companies expanding in the us ultimately sofinnova venture partners would shift its focus toward investments in domestic us companies   sofinnova partners completed fundraising for sofinnova capital its first private equity fund in france with €m of investor commitments sofinnovas investments in this fund include genset corporation as well as cerep egide and flamel s the reorganization of sofinnova into sofinnova partners and sofinnova venturesedit   sofinnova delisted itself from the paris exchange to raise capital privately through traditional private equity funds prior to the  reorganization sofinnova ventures raised three venture funds totaling m and sofinnova partners raised funds with €m in commitments   the global sofinnova organization restructured formally creating two separate management companies one for sofinnova ventures and one for sofinnova partners the reorganization was done on the basis of geography creating sofinnova ventures in the us and sofinnova partners in europe following a management buyout each of the management companies was solely owned by its respective management teams s the move to life science for sofinnovaedit   sofinnova ventures hires jim healy md phd and together he and mike powell phd rebuilt the sofinnova ventures ls brand with focus on clinical stage drug development companies   sofinnova ventures started its eirexecutive partner program in life sciences with its first eir barry selick following this several other eirsexecutive partners joined sofinnova ventures from then until  including jeff stein david kabakoff bill ringo strategic advisor goro takeda jay shepard george horner lars ekman and dan welch   sofinnova ventures and sofinnova partners first sponsored the sofinnova biopharm partnering conference in japan headed up by sofinnovas goro takeda in  the conference teamed up with biotechnology industry organization making this the largest biopartnering meeting in japan   svp vii was raised which was sofinnova ventures first fund that was overwhelmingly focused on life science  with emphasis on drug development their next fund svp viii in  was exclusively  life science at the same time sofinnova partners in paris moved from a balanced itls venture firm to one that was predominantly focused on life science   sofinnova ventures made its last it investment enovix the remaining it team was active for several years after this to monitor and monetize the final it investments s new growth initiatives at sofinnovaedit   sofinnova partners started their green seed fund and hired joško bobanović to manage this new initiative in  this seed fund initiative was announced in conjunction with the sofinnova capital vii announcement   sofinnova ventures worked with general partner garheng kong to spin out a new fund called healthquest capital hqcs mandate is to provide growth capital to companies transforming healthcare with a focus on companies other than drug development hqc raised their second fund at m in  and transitioned to further independence from the parent sofinnova ventures organization   sofinnova partners announced the first closing of sofinnova industrial biotech i at € million the fund dedicated to renewable chemistry follows a series of  investments in the sector since  it will leverage an experienced and dedicated team initially composed of denis lucquin managing partner joško bobanović partner michael krel principal and guillaume baxter senior associate referencesedit  a b c d based on capital raised since inception source private equity intelligence done deals venture capitalists tell their stories  p  the new venturers inside the highstakes world of venture capital  p  sofinnova sa public repurchase offering french sofinnova venturesedit sofinnova ventures business week profile distillations university of toronto sofinnova partnersedit accent to expand with investment from sofinnova partners external linksedit sofinnova ventures us  company website sofinnova partners france  company website v t e private equity and venture capital investment firms investment strategy venture growth mezzanine secondaries leveraged buyout history history of private equity and venture capital early history of private equity private equity in the s private equity in the s private equity in the s investors angel investor commercial bank corporate venture capital crowdfunding family office endowment fund of funds highnetworth individual institutional investor insurance company investment bank merchant bank pension fund sovereign wealth fund private equity firms venture capital firms portfolio companies retrieved from httpsenwikipediaorgwindexphptitlesofinnovaoldid categories companies established in companies based in san franciscoventure capital firms of the united stateslife sciences industryhidden categories pages using deprecated image syntax navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages add links this page was last edited on  june  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view sofinnova  wikipedia sofinnova from wikipedia the free encyclopedia jump to navigation search sofinnova is the name shared by two venture capital firms sofinnova ventures and sofinnova partners the name sofinnova is believed to be a contraction of the french société de financement de l’innovation or innovation venture capital company both firms trace their roots back to sofinnova sa an investment institution founded in paris in  the two firms have raised b since inception and shared a similar investment strategy of investing in the life science and technology sectors the two sister firms distinguish themselves on the basis of their target geographies and have been fully independent since  sofinnova ventures has offices in menlo park ca and san diego ca and focuses largely on us biotech investments with  allocation for europe sofinnova partners is based in paris and focuses primarily on european biotech and cleantech investments with a similar reciprocal allocation for the us sofinnova ventures and sofinnova partners have had historically some of the same limited partners and have coinvested together in selected companies including flamel cerep genset actelion preglem movetis ascendis obseva auris and nucana both firms work together in a collegial way to exchange information and due diligence in each others respective geographies the firms do not have an obligation to show each other deals or to coinvest but historically have coinvested together in  of their collective investments sofinnova ventures usaedit sofinnova ventures type private industry private equity founded  headquarters menlo park ca united states key people jim healy md phd mike powell phd anand mehra md lars ekman md david kabakoff phd dan welch cory freeland phd tommy nguyen md phd nathalie auber hooman shalavi charlotte shropshire alain azan retired jean deleage deceased products venture capital total assets b number of employees  website wwwsofinnovacom sofinnova ventures is an independent venture capital firm based in menlo park with b capital under management investmentsedit sofinnova ventures has been an active venture investor investing in some wellknown venture investments of the period sofinnova invested in collagen aesthetics biogen genentech tandon tandem computers and printonix tumbleweed and phonecom sofinnova ventures funded several of these as startups that developed into large international companies more recently sofinnova ventures has backed companies including millennium pharmaceuticals kosan biosciences actelion intermune seattle genetics cotherix threshold pharmaceuticals prestwick preglem movetis intellikine amarin corporation salveo and labrys the san francisco office of sofinnova ventures was often remembered for having an original  ft mosasaurus in the office of one of the managing partners mike powell sofinnova ventures closed their san francisco office in  and combined their bay area offices into a single office on sand hill road in menlo park sofinnova ventures has raised several venture capital funds see table the earlier funds svp i through v were predominantly information technology it wherein the later funds were predominantly life science focused svp viii and ix were exclusively life science only with emphasis on phase  and  drug development svp iv was sofinnova ventures initial fund after the reorganization of sofinnova in  each of the funds from svp v through svp ix exceeded the target raise and closed at the maximum amount as allowed by the limited partner agreements year amount fund  m sofinnova venture partners i  m sofinnova venture partners ii  m sofinnova venture partners iii  m sofinnova venture partners iv  m sofinnova venture partners v  m sofinnova venture partners vi  m sofinnova venture partners vii  m sofinnova venture partners viii  m sofinnova venture partners ix source private equity intelligence and sofinnova sofinnova partners franceedit sofinnova partners type private industry private equity founded  headquarters paris france key people denis lucquin antoine papiernik rafaele tordjman graziano seghezzi henrijette richter monique saulnier jeanbernard schmidt retired jean deleage deceased products venture capital total assets € billion website wwwsofinnovafr sofinnova partners is an independent venture capital firm based in paris with approximately € billion of capital the firm invests in early stage companies and corporate spinoffs in clean technology and life science sofinnova has financed more than  companies in europe since inception  of which more than  have successfully completed an initial public offering and more than  have been acquired by strategic buyers investmentsedit following the separation of the two firms sofinnova partners completed fundraising for its third private equity fund sofinnova capital iii with €m among the investments in this fund are innate maximiles and novuspharma sofinnovas fourth fund which raised €m of capital made sofinnova one of the largest venture firms in europe at the time in  sofinnova partners was named “fund of the year” by private equity international and “vc techno house of the year ” by the european venture capital journal evcj which described sofinnovas fundraising as the “fundraising of the year ” this fund invested in a number of companies including taptu sofinnova partners has raised several venture capital funds see table year amount fund  €m sofinnova capital i  €m sofinnova capital ii  €m sofinnova capital iii  €m sofinnova capital iv  €m sofinnova capital v  €m sofinnova capital vi  €m sofinnova capital vii  €m sofinnova capital viii source private equity intelligence and sofinnova historyedit history of private equity and venture capital early history origins of modern private equity the s leveraged buyout boom the s leveraged buyout and the venture capital bubble the s dotcom bubble to the credit crunch v t e s the founding of sofinnovaedit   sofinnova was founded with the backing of several french financial institutions most notably crédit national and was notable at the time for creating the first american style venture capital firm in france peter brooke the founder of ta associates was a board member of sofinnova sa in its early years sofinnova sa quickly established a presence in the european market through the formation of sofinnova partners in paris sofinnova sa owned this firm from  until    sofinnova became the first european venture company to enter the us market launching its us affiliate sofinnova inc sofinnova ventures sofinnova cofounder jean deleage who would later cofound us venture firm burr egan deleage  co was appointed the head of the us operation sofinnovas us business gained attention for its role as an early backer of tandem computers and genentech in the early s   sofinnova cofounder jean deleage established the american subsidiary of sofinnova called sofinnova inc in san francisco which eventually became sofinnova ventures deleage departed sofinnova in  to cofound another venture capital firm burr egan deleage  co in  working with deleage sofinnova developed a partnership with burr egan deleage  co and ultimately other us firms jeanbernard schmidt who would later serve as chairman of sofinnova was named the head of us operations of sofinnova inc s the early growth of sofinnovaedit   sofinnova completed an initial public offering with a listing on the paris stock exchange   alain azan moved to san francisco to take over management of sofinnova ventures replacing jeanbernard schmidt schmidt would be named chairman of sofinnova retaining that position through  sofinnova ventures completed fundraising for svp i which was an private equity fund originally intended to invest in european companies expanding in the us ultimately sofinnova venture partners would shift its focus toward investments in domestic us companies   sofinnova partners completed fundraising for sofinnova capital its first private equity fund in france with €m of investor commitments sofinnovas investments in this fund include genset corporation as well as cerep egide and flamel s the reorganization of sofinnova into sofinnova partners and sofinnova venturesedit   sofinnova delisted itself from the paris exchange to raise capital privately through traditional private equity funds prior to the  reorganization sofinnova ventures raised three venture funds totaling m and sofinnova partners raised funds with €m in commitments   the global sofinnova organization restructured formally creating two separate management companies one for sofinnova ventures and one for sofinnova partners the reorganization was done on the basis of geography creating sofinnova ventures in the us and sofinnova partners in europe following a management buyout each of the management companies was solely owned by its respective management teams s the move to life science for sofinnovaedit   sofinnova ventures hires jim healy md phd and together he and mike powell phd rebuilt the sofinnova ventures ls brand with focus on clinical stage drug development companies   sofinnova ventures started its eirexecutive partner program in life sciences with its first eir barry selick following this several other eirsexecutive partners joined sofinnova ventures from then until  including jeff stein david kabakoff bill ringo strategic advisor goro takeda jay shepard george horner lars ekman and dan welch   sofinnova ventures and sofinnova partners first sponsored the sofinnova biopharm partnering conference in japan headed up by sofinnovas goro takeda in  the conference teamed up with biotechnology industry organization making this the largest biopartnering meeting in japan   svp vii was raised which was sofinnova ventures first fund that was overwhelmingly focused on life science  with emphasis on drug development their next fund svp viii in  was exclusively  life science at the same time sofinnova partners in paris moved from a balanced itls venture firm to one that was predominantly focused on life science   sofinnova ventures made its last it investment enovix the remaining it team was active for several years after this to monitor and monetize the final it investments s new growth initiatives at sofinnovaedit   sofinnova partners started their green seed fund and hired joško bobanović to manage this new initiative in  this seed fund initiative was announced in conjunction with the sofinnova capital vii announcement   sofinnova ventures worked with general partner garheng kong to spin out a new fund called healthquest capital hqcs mandate is to provide growth capital to companies transforming healthcare with a focus on companies other than drug development hqc raised their second fund at m in  and transitioned to further independence from the parent sofinnova ventures organization   sofinnova partners announced the first closing of sofinnova industrial biotech i at € million the fund dedicated to renewable chemistry follows a series of  investments in the sector since  it will leverage an experienced and dedicated team initially composed of denis lucquin managing partner joško bobanović partner michael krel principal and guillaume baxter senior associate referencesedit  a b c d based on capital raised since inception source private equity intelligence done deals venture capitalists tell their stories  p  the new venturers inside the highstakes world of venture capital  p  sofinnova sa public repurchase offering french sofinnova venturesedit sofinnova ventures business week profile distillations university of toronto sofinnova partnersedit accent to expand with investment from sofinnova partners external linksedit sofinnova ventures us  company website sofinnova partners france  company website v t e private equity and venture capital investment firms investment strategy venture growth mezzanine secondaries leveraged buyout history history of private equity and venture capital early history of private equity private equity in the s private equity in the s private equity in the s investors angel investor commercial bank corporate venture capital crowdfunding family office endowment fund of funds highnetworth individual institutional investor insurance company investment bank merchant bank pension fund sovereign wealth fund private equity firms venture capital firms portfolio companies retrieved from httpsenwikipediaorgwindexphptitlesofinnovaoldid categories companies established in companies based in san franciscoventure capital firms of the united stateslife sciences industryhidden categories pages using deprecated image syntax navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages add links this page was last edited on  june  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view sofinnova  wikipedia sofinnova from wikipedia the free encyclopedia jump to navigation search sofinnova is the name shared by two venture capital firms sofinnova ventures and sofinnova partners the name sofinnova is believed to be a contraction of the french société de financement de l’innovation or innovation venture capital company both firms trace their roots back to sofinnova sa an investment institution founded in paris in  the two firms have raised b since inception and shared a similar investment strategy of investing in the life science and technology sectors the two sister firms distinguish themselves on the basis of their target geographies and have been fully independent since  sofinnova ventures has offices in menlo park ca and san diego ca and focuses largely on us biotech investments with  allocation for europe sofinnova partners is based in paris and focuses primarily on european biotech and cleantech investments with a similar reciprocal allocation for the us sofinnova ventures and sofinnova partners have had historically some of the same limited partners and have coinvested together in selected companies including flamel cerep genset actelion preglem movetis ascendis obseva auris and nucana both firms work together in a collegial way to exchange information and due diligence in each others respective geographies the firms do not have an obligation to show each other deals or to coinvest but historically have coinvested together in  of their collective investments sofinnova ventures usaedit sofinnova ventures type private industry private equity founded  headquarters menlo park ca united states key people jim healy md phd mike powell phd anand mehra md lars ekman md david kabakoff phd dan welch cory freeland phd tommy nguyen md phd nathalie auber hooman shalavi charlotte shropshire alain azan retired jean deleage deceased products venture capital total assets b number of employees  website wwwsofinnovacom sofinnova ventures is an independent venture capital firm based in menlo park with b capital under management investmentsedit sofinnova ventures has been an active venture investor investing in some wellknown venture investments of the period sofinnova invested in collagen aesthetics biogen genentech tandon tandem computers and printonix tumbleweed and phonecom sofinnova ventures funded several of these as startups that developed into large international companies more recently sofinnova ventures has backed companies including millennium pharmaceuticals kosan biosciences actelion intermune seattle genetics cotherix threshold pharmaceuticals prestwick preglem movetis intellikine amarin corporation salveo and labrys the san francisco office of sofinnova ventures was often remembered for having an original  ft mosasaurus in the office of one of the managing partners mike powell sofinnova ventures closed their san francisco office in  and combined their bay area offices into a single office on sand hill road in menlo park sofinnova ventures has raised several venture capital funds see table the earlier funds svp i through v were predominantly information technology it wherein the later funds were predominantly life science focused svp viii and ix were exclusively life science only with emphasis on phase  and  drug development svp iv was sofinnova ventures initial fund after the reorganization of sofinnova in  each of the funds from svp v through svp ix exceeded the target raise and closed at the maximum amount as allowed by the limited partner agreements year amount fund  m sofinnova venture partners i  m sofinnova venture partners ii  m sofinnova venture partners iii  m sofinnova venture partners iv  m sofinnova venture partners v  m sofinnova venture partners vi  m sofinnova venture partners vii  m sofinnova venture partners viii  m sofinnova venture partners ix source private equity intelligence and sofinnova sofinnova partners franceedit sofinnova partners type private industry private equity founded  headquarters paris france key people denis lucquin antoine papiernik rafaele tordjman graziano seghezzi henrijette richter monique saulnier jeanbernard schmidt retired jean deleage deceased products venture capital total assets € billion website wwwsofinnovafr sofinnova partners is an independent venture capital firm based in paris with approximately € billion of capital the firm invests in early stage companies and corporate spinoffs in clean technology and life science sofinnova has financed more than  companies in europe since inception  of which more than  have successfully completed an initial public offering and more than  have been acquired by strategic buyers investmentsedit following the separation of the two firms sofinnova partners completed fundraising for its third private equity fund sofinnova capital iii with €m among the investments in this fund are innate maximiles and novuspharma sofinnovas fourth fund which raised €m of capital made sofinnova one of the largest venture firms in europe at the time in  sofinnova partners was named “fund of the year” by private equity international and “vc techno house of the year ” by the european venture capital journal evcj which described sofinnovas fundraising as the “fundraising of the year ” this fund invested in a number of companies including taptu sofinnova partners has raised several venture capital funds see table year amount fund  €m sofinnova capital i  €m sofinnova capital ii  €m sofinnova capital iii  €m sofinnova capital iv  €m sofinnova capital v  €m sofinnova capital vi  €m sofinnova capital vii  €m sofinnova capital viii source private equity intelligence and sofinnova historyedit history of private equity and venture capital early history origins of modern private equity the s leveraged buyout boom the s leveraged buyout and the venture capital bubble the s dotcom bubble to the credit crunch v t e s the founding of sofinnovaedit   sofinnova was founded with the backing of several french financial institutions most notably crédit national and was notable at the time for creating the first american style venture capital firm in france peter brooke the founder of ta associates was a board member of sofinnova sa in its early years sofinnova sa quickly established a presence in the european market through the formation of sofinnova partners in paris sofinnova sa owned this firm from  until    sofinnova became the first european venture company to enter the us market launching its us affiliate sofinnova inc sofinnova ventures sofinnova cofounder jean deleage who would later cofound us venture firm burr egan deleage  co was appointed the head of the us operation sofinnovas us business gained attention for its role as an early backer of tandem computers and genentech in the early s   sofinnova cofounder jean deleage established the american subsidiary of sofinnova called sofinnova inc in san francisco which eventually became sofinnova ventures deleage departed sofinnova in  to cofound another venture capital firm burr egan deleage  co in  working with deleage sofinnova developed a partnership with burr egan deleage  co and ultimately other us firms jeanbernard schmidt who would later serve as chairman of sofinnova was named the head of us operations of sofinnova inc s the early growth of sofinnovaedit   sofinnova completed an initial public offering with a listing on the paris stock exchange   alain azan moved to san francisco to take over management of sofinnova ventures replacing jeanbernard schmidt schmidt would be named chairman of sofinnova retaining that position through  sofinnova ventures completed fundraising for svp i which was an private equity fund originally intended to invest in european companies expanding in the us ultimately sofinnova venture partners would shift its focus toward investments in domestic us companies   sofinnova partners completed fundraising for sofinnova capital its first private equity fund in france with €m of investor commitments sofinnovas investments in this fund include genset corporation as well as cerep egide and flamel s the reorganization of sofinnova into sofinnova partners and sofinnova venturesedit   sofinnova delisted itself from the paris exchange to raise capital privately through traditional private equity funds prior to the  reorganization sofinnova ventures raised three venture funds totaling m and sofinnova partners raised funds with €m in commitments   the global sofinnova organization restructured formally creating two separate management companies one for sofinnova ventures and one for sofinnova partners the reorganization was done on the basis of geography creating sofinnova ventures in the us and sofinnova partners in europe following a management buyout each of the management companies was solely owned by its respective management teams s the move to life science for sofinnovaedit   sofinnova ventures hires jim healy md phd and together he and mike powell phd rebuilt the sofinnova ventures ls brand with focus on clinical stage drug development companies   sofinnova ventures started its eirexecutive partner program in life sciences with its first eir barry selick following this several other eirsexecutive partners joined sofinnova ventures from then until  including jeff stein david kabakoff bill ringo strategic advisor goro takeda jay shepard george horner lars ekman and dan welch   sofinnova ventures and sofinnova partners first sponsored the sofinnova biopharm partnering conference in japan headed up by sofinnovas goro takeda in  the conference teamed up with biotechnology industry organization making this the largest biopartnering meeting in japan   svp vii was raised which was sofinnova ventures first fund that was overwhelmingly focused on life science  with emphasis on drug development their next fund svp viii in  was exclusively  life science at the same time sofinnova partners in paris moved from a balanced itls venture firm to one that was predominantly focused on life science   sofinnova ventures made its last it investment enovix the remaining it team was active for several years after this to monitor and monetize the final it investments s new growth initiatives at sofinnovaedit   sofinnova partners started their green seed fund and hired joško bobanović to manage this new initiative in  this seed fund initiative was announced in conjunction with the sofinnova capital vii announcement   sofinnova ventures worked with general partner garheng kong to spin out a new fund called healthquest capital hqcs mandate is to provide growth capital to companies transforming healthcare with a focus on companies other than drug development hqc raised their second fund at m in  and transitioned to further independence from the parent sofinnova ventures organization   sofinnova partners announced the first closing of sofinnova industrial biotech i at € million the fund dedicated to renewable chemistry follows a series of  investments in the sector since  it will leverage an experienced and dedicated team initially composed of denis lucquin managing partner joško bobanović partner michael krel principal and guillaume baxter senior associate referencesedit  a b c d based on capital raised since inception source private equity intelligence done deals venture capitalists tell their stories  p  the new venturers inside the highstakes world of venture capital  p  sofinnova sa public repurchase offering french sofinnova venturesedit sofinnova ventures business week profile distillations university of toronto sofinnova partnersedit accent to expand with investment from sofinnova partners external linksedit sofinnova ventures us  company website sofinnova partners france  company website v t e private equity and venture capital investment firms investment strategy venture growth mezzanine secondaries leveraged buyout history history of private equity and venture capital early history of private equity private equity in the s private equity in the s private equity in the s investors angel investor commercial bank corporate venture capital crowdfunding family office endowment fund of funds highnetworth individual institutional investor insurance company investment bank merchant bank pension fund sovereign wealth fund private equity firms venture capital firms portfolio companies retrieved from httpsenwikipediaorgwindexphptitlesofinnovaoldid categories companies established in companies based in san franciscoventure capital firms of the united stateslife sciences industryhidden categories pages using deprecated image syntax navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages add links this page was last edited on  june  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view sofinnova  wikipedia sofinnova from wikipedia the free encyclopedia jump to navigation search sofinnova is the name shared by two venture capital firms sofinnova ventures and sofinnova partners the name sofinnova is believed to be a contraction of the french société de financement de l’innovation or innovation venture capital company both firms trace their roots back to sofinnova sa an investment institution founded in paris in  the two firms have raised b since inception and shared a similar investment strategy of investing in the life science and technology sectors the two sister firms distinguish themselves on the basis of their target geographies and have been fully independent since  sofinnova ventures has offices in menlo park ca and san diego ca and focuses largely on us biotech investments with  allocation for europe sofinnova partners is based in paris and focuses primarily on european biotech and cleantech investments with a similar reciprocal allocation for the us sofinnova ventures and sofinnova partners have had historically some of the same limited partners and have coinvested together in selected companies including flamel cerep genset actelion preglem movetis ascendis obseva auris and nucana both firms work together in a collegial way to exchange information and due diligence in each others respective geographies the firms do not have an obligation to show each other deals or to coinvest but historically have coinvested together in  of their collective investments sofinnova ventures usaedit sofinnova ventures type private industry private equity founded  headquarters menlo park ca united states key people jim healy md phd mike powell phd anand mehra md lars ekman md david kabakoff phd dan welch cory freeland phd tommy nguyen md phd nathalie auber hooman shalavi charlotte shropshire alain azan retired jean deleage deceased products venture capital total assets b number of employees  website wwwsofinnovacom sofinnova ventures is an independent venture capital firm based in menlo park with b capital under management investmentsedit sofinnova ventures has been an active venture investor investing in some wellknown venture investments of the period sofinnova invested in collagen aesthetics biogen genentech tandon tandem computers and printonix tumbleweed and phonecom sofinnova ventures funded several of these as startups that developed into large international companies more recently sofinnova ventures has backed companies including millennium pharmaceuticals kosan biosciences actelion intermune seattle genetics cotherix threshold pharmaceuticals prestwick preglem movetis intellikine amarin corporation salveo and labrys the san francisco office of sofinnova ventures was often remembered for having an original  ft mosasaurus in the office of one of the managing partners mike powell sofinnova ventures closed their san francisco office in  and combined their bay area offices into a single office on sand hill road in menlo park sofinnova ventures has raised several venture capital funds see table the earlier funds svp i through v were predominantly information technology it wherein the later funds were predominantly life science focused svp viii and ix were exclusively life science only with emphasis on phase  and  drug development svp iv was sofinnova ventures initial fund after the reorganization of sofinnova in  each of the funds from svp v through svp ix exceeded the target raise and closed at the maximum amount as allowed by the limited partner agreements year amount fund  m sofinnova venture partners i  m sofinnova venture partners ii  m sofinnova venture partners iii  m sofinnova venture partners iv  m sofinnova venture partners v  m sofinnova venture partners vi  m sofinnova venture partners vii  m sofinnova venture partners viii  m sofinnova venture partners ix source private equity intelligence and sofinnova sofinnova partners franceedit sofinnova partners type private industry private equity founded  headquarters paris france key people denis lucquin antoine papiernik rafaele tordjman graziano seghezzi henrijette richter monique saulnier jeanbernard schmidt retired jean deleage deceased products venture capital total assets € billion website wwwsofinnovafr sofinnova partners is an independent venture capital firm based in paris with approximately € billion of capital the firm invests in early stage companies and corporate spinoffs in clean technology and life science sofinnova has financed more than  companies in europe since inception  of which more than  have successfully completed an initial public offering and more than  have been acquired by strategic buyers investmentsedit following the separation of the two firms sofinnova partners completed fundraising for its third private equity fund sofinnova capital iii with €m among the investments in this fund are innate maximiles and novuspharma sofinnovas fourth fund which raised €m of capital made sofinnova one of the largest venture firms in europe at the time in  sofinnova partners was named “fund of the year” by private equity international and “vc techno house of the year ” by the european venture capital journal evcj which described sofinnovas fundraising as the “fundraising of the year ” this fund invested in a number of companies including taptu sofinnova partners has raised several venture capital funds see table year amount fund  €m sofinnova capital i  €m sofinnova capital ii  €m sofinnova capital iii  €m sofinnova capital iv  €m sofinnova capital v  €m sofinnova capital vi  €m sofinnova capital vii  €m sofinnova capital viii source private equity intelligence and sofinnova historyedit history of private equity and venture capital early history origins of modern private equity the s leveraged buyout boom the s leveraged buyout and the venture capital bubble the s dotcom bubble to the credit crunch v t e s the founding of sofinnovaedit   sofinnova was founded with the backing of several french financial institutions most notably crédit national and was notable at the time for creating the first american style venture capital firm in france peter brooke the founder of ta associates was a board member of sofinnova sa in its early years sofinnova sa quickly established a presence in the european market through the formation of sofinnova partners in paris sofinnova sa owned this firm from  until    sofinnova became the first european venture company to enter the us market launching its us affiliate sofinnova inc sofinnova ventures sofinnova cofounder jean deleage who would later cofound us venture firm burr egan deleage  co was appointed the head of the us operation sofinnovas us business gained attention for its role as an early backer of tandem computers and genentech in the early s   sofinnova cofounder jean deleage established the american subsidiary of sofinnova called sofinnova inc in san francisco which eventually became sofinnova ventures deleage departed sofinnova in  to cofound another venture capital firm burr egan deleage  co in  working with deleage sofinnova developed a partnership with burr egan deleage  co and ultimately other us firms jeanbernard schmidt who would later serve as chairman of sofinnova was named the head of us operations of sofinnova inc s the early growth of sofinnovaedit   sofinnova completed an initial public offering with a listing on the paris stock exchange   alain azan moved to san francisco to take over management of sofinnova ventures replacing jeanbernard schmidt schmidt would be named chairman of sofinnova retaining that position through  sofinnova ventures completed fundraising for svp i which was an private equity fund originally intended to invest in european companies expanding in the us ultimately sofinnova venture partners would shift its focus toward investments in domestic us companies   sofinnova partners completed fundraising for sofinnova capital its first private equity fund in france with €m of investor commitments sofinnovas investments in this fund include genset corporation as well as cerep egide and flamel s the reorganization of sofinnova into sofinnova partners and sofinnova venturesedit   sofinnova delisted itself from the paris exchange to raise capital privately through traditional private equity funds prior to the  reorganization sofinnova ventures raised three venture funds totaling m and sofinnova partners raised funds with €m in commitments   the global sofinnova organization restructured formally creating two separate management companies one for sofinnova ventures and one for sofinnova partners the reorganization was done on the basis of geography creating sofinnova ventures in the us and sofinnova partners in europe following a management buyout each of the management companies was solely owned by its respective management teams s the move to life science for sofinnovaedit   sofinnova ventures hires jim healy md phd and together he and mike powell phd rebuilt the sofinnova ventures ls brand with focus on clinical stage drug development companies   sofinnova ventures started its eirexecutive partner program in life sciences with its first eir barry selick following this several other eirsexecutive partners joined sofinnova ventures from then until  including jeff stein david kabakoff bill ringo strategic advisor goro takeda jay shepard george horner lars ekman and dan welch   sofinnova ventures and sofinnova partners first sponsored the sofinnova biopharm partnering conference in japan headed up by sofinnovas goro takeda in  the conference teamed up with biotechnology industry organization making this the largest biopartnering meeting in japan   svp vii was raised which was sofinnova ventures first fund that was overwhelmingly focused on life science  with emphasis on drug development their next fund svp viii in  was exclusively  life science at the same time sofinnova partners in paris moved from a balanced itls venture firm to one that was predominantly focused on life science   sofinnova ventures made its last it investment enovix the remaining it team was active for several years after this to monitor and monetize the final it investments s new growth initiatives at sofinnovaedit   sofinnova partners started their green seed fund and hired joško bobanović to manage this new initiative in  this seed fund initiative was announced in conjunction with the sofinnova capital vii announcement   sofinnova ventures worked with general partner garheng kong to spin out a new fund called healthquest capital hqcs mandate is to provide growth capital to companies transforming healthcare with a focus on companies other than drug development hqc raised their second fund at m in  and transitioned to further independence from the parent sofinnova ventures organization   sofinnova partners announced the first closing of sofinnova industrial biotech i at € million the fund dedicated to renewable chemistry follows a series of  investments in the sector since  it will leverage an experienced and dedicated team initially composed of denis lucquin managing partner joško bobanović partner michael krel principal and guillaume baxter senior associate referencesedit  a b c d based on capital raised since inception source private equity intelligence done deals venture capitalists tell their stories  p  the new venturers inside the highstakes world of venture capital  p  sofinnova sa public repurchase offering french sofinnova venturesedit sofinnova ventures business week profile distillations university of toronto sofinnova partnersedit accent to expand with investment from sofinnova partners external linksedit sofinnova ventures us  company website sofinnova partners france  company website v t e private equity and venture capital investment firms investment strategy venture growth mezzanine secondaries leveraged buyout history history of private equity and venture capital early history of private equity private equity in the s private equity in the s private equity in the s investors angel investor commercial bank corporate venture capital crowdfunding family office endowment fund of funds highnetworth individual institutional investor insurance company investment bank merchant bank pension fund sovereign wealth fund private equity firms venture capital firms portfolio companies retrieved from httpsenwikipediaorgwindexphptitlesofinnovaoldid categories companies established in companies based in san franciscoventure capital firms of the united stateslife sciences industryhidden categories pages using deprecated image syntax navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages add links this page was last edited on  june  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view   forbidden access is denied server error   forbidden access is denied you do not have permission to view this directory or page using the credentials that you supplied sofinnova venture partners vi l p  current holdings  fintelio sofinnova venture partners vi l p current holdings from f d investorsofinnova venture partners vi l p current positions sofinnova venture partners vi l p has disclosed  total holdings in their latest sec filings this investor has not filed a f which indicates it has under m in assets under management aum this investor has filed  activist d filings recently which suggests it takes an active role in influencing management sofinnova venture partners vi l p s top industries are chemicals and allied products sic   overview sec filings dg predictive value all sofinnova venture partners vi l p holdings are listed in the following table this data is sourced from dg and f filings green rows indicate new positions red rows indicate closed positions add this fundto your dashboard this is a list of d and g filings made since the last quarterly f report if any file dateformsecurity prevshares currentshares changepercent prev valuex current valuex changepercent ‑‑ sc da mrns  marinus pharmaceuticals inc     fintel ir  find the right investors for your company instantly fintel ir combines the comprehensive fintel ownership database with machine learning to provide advanced tools to make investor outreach fast and easy learn more now from the blog how to launch a hedge fund the piotroski score sofinnova venture partners vi l p  ceo founder businessman  profile directorpedianet  list of ceos founders board members and company directors sofinnova venture partners vi l p check out list of companies and businesses related to sofinnova venture partners vi l p find out sofinnova venture partners vi l p address and contact details view other people related to sofinnova venture partners vi l p  coworkers colleagues companions etc address  sand hill road suite  menlo park  ca companies related to sofinnova venture partners vi l p cikcompany namepositioncompany addressocera therapeutics inc owner  twin dolphin drive suite  redwood city anthera pharmaceuticals inc owner  industrial boulevard suite b hayward  sofinnova venture partners vi l p on the web persons related to sofinnova venture partners vi l p  ocera therapeutics incnamepositioncity capital gp llc owner new yorkdavidson aarondurhamgeorge b abercrombiedirector durhamgeorge b abercrombiedirector durhamgaurav aggarwalchief business officer south san franciscogaurav aggarwalchief business officer palo altoeric aguiarstamforderic aguiarminneapoliszisson alexdurhamvanlent annesan diegovanlent annepalo altoalain azanmenlo parkbaker biotech capital gp llc owner new yorkbaker brothers life sciences capital gp llc owner new yorkfelix bakernew yorkjulian bakernew yorkbdc capital inc owner montreal quebec canadajames c blair owner princetongavin brendadurhameric buatoismenlo parkstan bukofzerchief medical officer palo altomichael byrnescfo and treasurer palo altoregional et cooperatif desjardins capital owner montreal quebec canadajeanpaul castaignedirector durhamjeanpaul castaignedirector durhamjeanpaul castaignedirector palo altomcgowan danasan diegodrutz daviddurhammoore davidsan diegomoore davidpalo altoaaron davidsondirector durhamaaron davidsonmiamiaaron davidsondirector durhamwillard h deredirector thousand oakssec desjardinsinnovatechmontreal quebec canadaassociates domainprincetondomain partners vi lp owner princetondomain partners viii lpprincetoncorcoran donalddurhambrian h dovey owner princetondp vi associates lpprincetondp viii associates lpprincetonweber eckardpalo altoweber eckardsan diegorichard i eisenstadtvp finance  cfo durhamrichard i eisenstadtvp finance  cfo durhamlars ekmanla jollarousseau francksan diegorousseau franckpalo altovipin k gargpresident  ceo durhamvipin k gargpresident  ceo durhambrenda d gavinphiladelphiabrenda d gavindirector durhamlinda s graispresident and ceo menlo parklinda s graispresident and ceo san diegolinda s graispresident and ceo palo altohig ventures  tranzyme llc owner miamibrian k halak owner princetonjames healymenlo parkhig gp ii incmiamijeryl l hillemansan diegojeryl l hillemancfo and secretary palo altosteven p jamesdirector steven p jamesdirector palo altocastaigne jeanpauldurhamcastaigne jeanpaulsan diegocastaigne jeanpaulpalo altohilleman jerylpalo altojohn johnsondirector durhamjohn johnsondirector durhamkim p kamdarprincetonnina s kjellsondirector menlo parknina s kjellsondirector palo altonina s kjellsondirector menlo parknina s kjellsondirector menlo parkgordana kosuticvp clinical and regulatory durhamekman larssan diegoekman larspalo altograis lindasan diegograis lindapalo altodana s mcgowancfo and secretary san diegopete mcnerneyminneapolispete mcnerneyminneapolispowell michaelsan diegopowell michaelpalo altosami mnaymnehmiamidavid moorevp commercial operations durhamdavid moorevp commercial operations durhamkjellson ninasan diegokjellson ninapalo altorajiv patnichief development officer palo altomichael powelldirector michael powelldirector menlo parkmichael powelldirector palo altoshah pratiksan diegoshah pratikpalo altoquaker bio ventures lp owner philadelphiaquaker bioventures capital lpphiladelphiaeisenstadt richarddurhamfranck rousseauchief medical officer durhamfranck rousseauchief medical officer durhamfranck rousseauchief medical  dev officer palo altokathleen k schoemaker owner princetonnimesh shahprincetonpratik shahminneapolispratik shahminneapolispratik shahdirector palo altosofinnova management vi llcmenlo parksofinnova venture affiliates vi lpmenlo parksofinnova venture partners vi gmbh  co kgmenlo parkrhonda l stanleydurhamanthony tamermiamisharon tetlowacting cfo  treasurer palo altohelmut thomassenior vp rd durhamhelmut thomassenior vp rd durhamjames e thomasjames e thomasminneapolisjames e thomasminneapolisjames e thomasminneapolisthomas mcnerney  partners ii lpminneapolisthomas mcnerney  partners ii lpminneapolisthomas mcnerney  partners ii lpminneapolisthomas mcnerney  partners ii llcminneapolisthomas mcnerney  partners ii llcminneapolisthomas mcnerney  partners llcminneapolisthomas mcnerney  partners llcminneapolisthomas mcnerney  partners llcminneapolisthomas mcnerney  partners lpminneapolisthomas mcnerney  partners lp owner minneapolisthomas mcnerney  partners lpminneapolistmp associates ii lpminneapolistmp associates ii lpminneapolistmp associates ii lpminneapolistmp associates lpminneapolistmp associates lpminneapolistmp associates lpminneapolistmp nominee ii llcminneapolistmp nominee ii llcminneapolistmp nominee llcminneapolistmp nominee llcminneapolistmp nominee llcminneapolisjesse i treu owner princetonanne vanlentdirector princetonanne vanlentdurhamanne vanlentdirector durhamanne vanlentdirector durhamanne vanlentdirector palo altogarg vipindurhamnicole vitullo owner princetoneckard weberdirector south san franciscoeckard webersan diegoeckard weberdirector san diegoeckard weberdirector palo altowendall wierengadirector palo altowendall d wierengadirector san diegoalex zissonminneapolisalex zissondirector durhamalex zissondirector durhamalex zissonminneapolispersons related to sofinnova venture partners vi l p  anthera pharmaceuticals incnamepositioncityalain azanmenlo parkalain azanmenlo parkannette bianchidirector san brunoannette bianchisan brunoeric buatoismenlo parkklara dickinsonchief regulatory officer south san franciscobogdan dziurzynski haywardbogdan dziurzynskihaywardbogdan dziurzynskidirector haywardbogdan dziurzynskidirector haywardbogdan dziurzynski haywardsteven b engle san diegosteven b engleberkeleysteven b engle haywardursula fritschvp glob reg  compliance haywardbrent furseparsippanyjames healydirector menlo parkjames healy haywardjames healydirector haywardchristopher s henney seattlechristopher s henney haywardchristopher s henney haywardchristopher s henneydirector haywardcolin hislopchief medical officer haywardcolin hislopchief medical officer haywardcolin hislopchief medical officer haywardsamuel d isalynew yorksamuel d isalynew yorksamuel d isalynew yorksamuel d isalynew yorkgeorgina kilfoilsvp prod dev  project mngm haywardgeorgina kilfoilsvpproduct dev project mgmt haywardgeorgina kilfoilsvpproduct dev project mgmt haywardstephen lauvp corp  business dev haywarda rachel lehenydirector haywardmay liuprincipal accounting officer haywardchristopher p lowechief financial officer  cbo haywardchristopher p lowecfo and cbo haywardchristopher p lowecfo and cbo haywardchristopher p lowecfo and chief business officer haywardbrian mueller novatobrian muellerhaywardbrian mueller haywardbrian mueller haywarddebra odinkchief technology officer haywarddebra odinkchief technology officer haywarddebra odinkchief technology officer haywardcharles v olsonchief technology officer haywardorbimed advisors llcdirector new yorkorbimed advisors llcdirector new yorkorbimed advisors llc owner new yorkorbimed advisors llcdirector new yorkorbimed capital gp iv llcnew yorkorbimed capital gp iv llcnew yorkorbimed capital gp iv llcnew yorkjames penningtonhaywardjames e penningtonhaywardmichael powellmenlo parkphilip sager haywardphilip sager haywardphilip sager haywardalan e salzmansan brunoalan e salzmansan brunodonald j santeldirector haywardwilliam r shanahan jrchief medical officer san diegosofinnova management vi llcsan franciscosofinnova management vi llc owner san franciscosofinnova management vi llcmenlo parksofinnova venture affiliates vi lpmenlo parksofinnova venture partners vi gmbh  co kgmenlo parkdaniel k spiegelman haywarddaniel k spiegelman haywarddaniel k spiegelmandirector haywarddavid e thompsondirector haywarddavid e thompson haywarddavid e thompson haywardjohn craig thompsonpresident  ceo san diegopeter a thompsondirector haywardjoaquim triassr vp preclinical developmen haywardpaul f truexexecutive chaiman haywardpaul f truexpresident and ceo haywardpaul f truexpresident and ceo haywardpaul f truexpresident and ceo haywardpaul f truexpresident and ceo haywardvantagepoint venture associates iv llc owner san brunovantagepoint venture associates iv llc owner san brunovantagepoint venture partners iv lpsan brunovantagepoint venture partners iv lpsan brunovantagepoint venture partners iv principals fund lpsan brunovantagepoint venture partners iv principals fund lpsan brunovantagepoint venture partners iv q lpsan brunovantagepoint venture partners iv q lpsan brunozenyaku kogyo co ltdtokyosanford s zweifach haywardsanford s zweifach haywardsanford s zweifach hayward potentially same personnamecitycountrysofinnova venture partners vi l psan franciscocasofinnova venture partners vi l pmenlo parkca michael f powell phd executive profile  biography  bloomberg july    pm et capital markets company overview of sofinnova ventures inc snapshotpeople  overviewboard memberscommittees executive profile michael f powell phdgeneral partner and managing general partner  sofinnova ventures incagetotal calculated compensationthis person is connected to  board members in  different organizations across  different industriessee board relationships background dr michael f powell also known as mike phd is a partner of sofinnova venture partners x lp and sofinnova venture partners ix lp dr powell serves as scientific advisor at the institute for oneworld health he serves as a scientific advisor to the controlled release society he serves as a general partner and managing general partner of sofinnova ventures inc sofinnova venture partners vii lp and sofinnova venture partners vi lp he joined sofinnova  ventures inc in  as a member of the life science investment team he focused on clinical stage product companies particularly in the oncology endocrine and neurology areas he has  years of pharmaceutical development experience he was a faculty member at university of california from  to  he was a strategic advisor to one world health he was an adjunct associate professor of pharmacuetical chemistry at the university of kansas he served as a group head of drug deliverygroup leader of drug delivery at genentech inc from december  to june  and focused on developing new therapeutics from september  to december  he served as director of product development at epimmune inc alternate name cytel corp he was cofounder of epimmune and was responsible for its early growth that culminated in a successful initial public offer dr powell served as a senior scientist at syntex corporation he served as a scientist and project team leader at syntex research where he has held several positions that provided an appreciation and overview of the many aspects of traditional drug development he has been the chairman at mirna therapeutics inc since december  he serves as the chairman of dauntless pharmaceuticals inc and checkmate pharmaceuticals inc he has been a director of labrys biologics inc since january   he has been a nonemployee director of mirna therapeutics inc since  he serves as a director of intellikine llc tensys medical inc and alvine pharmaceuticals inc he has been an independent director at algorx pharmaceuticals inc since march  he has been a director of galera therapeutics inc since november   he serves as a director of david pharmaceuticals innocol and intermune pharmaceuticals he is a founding venture advisory board member of the iavi innovation fund he serves on the university of kansas board of iami institute for the advancement of medical innovation he serves as a trustee for washington university in st louis mr powell serves as a director at dauntless  inc he served as director of ocera therapeutics inc since june  until june   he served as a member of scientific advisory board at aduro biotech inc until december   and aradigm corporation he served as a director of trius therapeutics llc from february  to may   he served as a director of saegis pharmaceuticals inc and intermune inc dr powell served as a director of journal at pharmaceutical sciences he served as a director of threshold pharmaceuticals inc from  to november  anesiva inc since december  orexigen therapeutics inc from january  to april   and corgentech inc since december  he served as a director of cibolan gold corp alternate name general metals corporation from may   to december   he served as a director of seattle genetics inc since april  he serves as a board president of avac aids vaccine advocacy coalition he served as a director at ascenta therapeutics inc and diobex inc he served as an advisormember of advisory board at bill  melinda gates foundation he was on editorial board member of j pharm sci he served as director of catalyst biosciences inc in  he received the honor of being the first scientist from the biotechnology industry to be elected a fellow of the american association of pharmaceutical scientists he is the author of nearly  publications and books and  clinical products including a page treatise on vaccine design dr powell received a phd in physical chemistry from the university of toronto in  post doctored in bio organic chemistry at the university of california and holds a bs from the university of torontoread full background corporate headquarters  sand hill roadmenlo park california united statesphone fax  board members memberships directortensys medical incdirectoralvine pharmaceuticals incdirectorintellikine llcchairmancheckmate pharmaceuticals incchairmandauntless pharmaceuticals incdirectordauntless  incpresentchairman of the boardmirna therapeutics incpresentdirectorlabrys biologics incpresentdirectorgalera therapeutics inc education postdoctoral training university of californiaphd university of torontobs university of toronto other affiliations aradigm corporationepimmune incgenentech incseattle genetics incintermune inctensys medical incsyntex corporationuniversity of californiacorgentech incsaegis pharmaceuticals incanesiva incaduro biotech incthreshold pharmaceuticals incsofinnova venture partners vi lpuniversity of torontobill  melinda gates foundationcatalyst biosciences incorexigen therapeutics inccibolan gold corporationascenta therapeutics incdiobex inctrius therapeutics llcocera therapeutics incthe institute for oneworld healthalvine pharmaceuticals incsofinnova venture partners vii lpintellikine llcmirna therapeutics incsofinnova venture partners viii lpgalera therapeutics inclabrys biologics incsofinnova venture partners ix lpcheckmate pharmaceuticals incdauntless pharmaceuticals incsofinnova venture partners x lpdauntless  inc annual compensation there is no annual compensation data available stocks options there is no stock options data available total compensation there is no total compensation data available request profile update   the information and data displayed in this profile are created and managed by sp global market intelligence a division of sp global bloombergcom does not create or control the content for inquiries please contact sp global market intelligence directly by clicking here stock quotes market data is delayed at least  minutes company lookup competitor compensationthere is no competitor compensation data available sponsored financial commentaries sponsored links browse companies a b c d e f g h i j k l m n o p q r s t u v w x y z              request profile update only a company representative may request an update for the company profile documentation will be required to contact sofinnova ventures inc please visit  company data is provided by sp global market intelligence please use this form to report any data issues information missing  please enter your information in the following fields company name your name your email address your phone number type of data overview executives key developments similar companies transactions update needed all data changes require verification from public sources please include the correct value or values and a source where we can verify cancel submit your requested update has been submitted our data partners will research the update request and update the information on this page if necessary research and followup could take several weeks if you have questions you can contact them at bwwebmasterbusinessweekcom close sofinnova venture partners vi l p  ceo founder businessman  profile directorpedianet  list of ceos founders board members and company directors sofinnova venture partners vi l p check out list of companies and businesses related to sofinnova venture partners vi l p find out sofinnova venture partners vi l p address and contact details view other people related to sofinnova venture partners vi l p  coworkers colleagues companions etc address  geary street th floor san francisco  ca companies related to sofinnova venture partners vi l p cikcompany namepositioncompany addressmarinus pharmaceuticals inc n radnor chester rd suite  radnor anthera pharmaceuticals inc owner  industrial boulevard suite b hayward orexigen therapeutics inc owner  n torrey pines ct suite  la jolla  sofinnova venture partners vi l p on the web persons related to sofinnova venture partners vi l p  marinus pharmaceuticals incnamepositioncitybarber alanbranfordmehra anandbranfordmehra md anandbranfordmehra md anandnew havengopka antonbranfordgopka antonnew havenalain azansan franciscoalain azanmenlo parkjames c blairprincetonstephen m blochdirector westportstephen m blochnew havenstephen m blochdirector westporteric buatoissan franciscoeric buatoismenlo parkstuart cablebostoncanaan partners vii llcwestfordcanaan partners vii llcwestportcanaan vii l p owner westfordcanaan vii l pdirector westportcanaan vii lpdirector westportenrique j carrazanadirector hawthorneenrique j carrazanadirector new havenchristopher michael cashmanchairman and ceo new havenchristopher michael cashmanpresident and ceo new havenchristopher michael cashmanpresident and ceo radnorcashman christopherbranfordcashman christophernew havenassociates domainprincetondomain partners vi lp owner princetonmichael r doughertybrian h doveyprincetondp vi associates lp owner princetongail m farfelchief clinical dev  reg offic new havengail m farfelchief clinical dev  reg radnorseth hz fischerdirector san diegoanton gopkadirector new havenbrian k halakprincetonpenner jr harrybranfordpenner harrybranfordpenner harrynew havenrein harrybranfordrein harrynew havenjames healybrisbanejames healymenlo parkkrayacich johnbranfordkim p kamdarprincetonshaw kennethbranfordmasuoka k loriannesan carlostimothy m maylebendirector ann arbortimothy m maylebendirector new havenanand mehra owner menlo parkanand mehradirector menlo parkvitullo nicolenew havenvitullo nicolebranfordalbena patronevachief medical officer radnormichael powellmichael powellmenlo parkkathleen k schoemakerprincetonnimesh shahprincetonjay sheparddirector cupertinojay sheparddirector new havenedward f smithcfo philadelphiaedward f smithnew havenedward f smithcfo radnorsofinnova management vi llcsan franciscosofinnova management vi llcmenlo parksofinnova venture affiliates vi lpmenlo parksofinnova venture affiliates vi lpmenlo parksofinnova venture partners vi gmbh  co kgmenlo parksofinnova venture partners vi gmbh  co kgmenlo parkbloch stephenbranfordbloch md stephenbranfordbloch md stephennew havenmayleben timothynew havenmayleben timothybranfordjesse i treuprincetonnicole vitullodirector richmondnicole vitullodirector princetonpersons related to sofinnova venture partners vi l p  anthera pharmaceuticals incnamepositioncityalain azanmenlo parkalain azanmenlo parkannette bianchidirector san brunoannette bianchisan brunoeric buatoismenlo parkklara dickinsonchief regulatory officer south san franciscobogdan dziurzynski haywardbogdan dziurzynskihaywardbogdan dziurzynskidirector haywardbogdan dziurzynskidirector haywardbogdan dziurzynski haywardsteven b engle san diegosteven b engleberkeleysteven b engle haywardursula fritschvp glob reg  compliance haywardbrent furseparsippanyjames healydirector menlo parkjames healy haywardjames healydirector haywardchristopher s henney seattlechristopher s henney haywardchristopher s henney haywardchristopher s henneydirector haywardcolin hislopchief medical officer haywardcolin hislopchief medical officer haywardcolin hislopchief medical officer haywardsamuel d isalynew yorksamuel d isalynew yorksamuel d isalynew yorksamuel d isalynew yorkgeorgina kilfoilsvp prod dev  project mngm haywardgeorgina kilfoilsvpproduct dev project mgmt haywardgeorgina kilfoilsvpproduct dev project mgmt haywardstephen lauvp corp  business dev haywarda rachel lehenydirector haywardmay liuprincipal accounting officer haywardchristopher p lowechief financial officer  cbo haywardchristopher p lowecfo and cbo haywardchristopher p lowecfo and cbo haywardchristopher p lowecfo and chief business officer haywardbrian mueller novatobrian muellerhaywardbrian mueller haywardbrian mueller haywarddebra odinkchief technology officer haywarddebra odinkchief technology officer haywarddebra odinkchief technology officer haywardcharles v olsonchief technology officer haywardorbimed advisors llcdirector new yorkorbimed advisors llcdirector new yorkorbimed advisors llc owner new yorkorbimed advisors llcdirector new yorkorbimed capital gp iv llcnew yorkorbimed capital gp iv llcnew yorkorbimed capital gp iv llcnew yorkjames penningtonhaywardjames e penningtonhaywardmichael powellmenlo parkphilip sager haywardphilip sager haywardphilip sager haywardalan e salzmansan brunoalan e salzmansan brunodonald j santeldirector haywardwilliam r shanahan jrchief medical officer san diegosofinnova management vi llcsan franciscosofinnova management vi llc owner san franciscosofinnova management vi llcmenlo parksofinnova venture affiliates vi lpmenlo parksofinnova venture partners vi gmbh  co kgmenlo parkdaniel k spiegelman haywarddaniel k spiegelman haywarddaniel k spiegelmandirector haywarddavid e thompsondirector haywarddavid e thompson haywarddavid e thompson haywardjohn craig thompsonpresident  ceo san diegopeter a thompsondirector haywardjoaquim triassr vp preclinical developmen haywardpaul f truexexecutive chaiman haywardpaul f truexpresident and ceo haywardpaul f truexpresident and ceo haywardpaul f truexpresident and ceo haywardpaul f truexpresident and ceo haywardvantagepoint venture associates iv llc owner san brunovantagepoint venture associates iv llc owner san brunovantagepoint venture partners iv lpsan brunovantagepoint venture partners iv lpsan brunovantagepoint venture partners iv principals fund lpsan brunovantagepoint venture partners iv principals fund lpsan brunovantagepoint venture partners iv q lpsan brunovantagepoint venture partners iv q lpsan brunozenyaku kogyo co ltdtokyosanford s zweifach haywardsanford s zweifach haywardsanford s zweifach haywardpersons related to sofinnova venture partners vi l p  orexigen therapeutics incnamepositioncityheather s aceevp global human resources san diegomoshe arkin herzeliamoshe arkinherzeliacarol a baumvp commercialization la jollabaupost group llcmabostonjames c blair owner princetonlouis c bockdirector foster citylouis c bockdirector foster citylouis c bockdirector san diegolouis c bockdirector foster citylouis c bockdirector la jollamark d boothchief commercial officer la jolladoron breen tel avivdovey brianla jollafranklin p bymastervp of neuroscience san diegofranklin p bymastervp neuroscience la jollathomas r cannellevp coo pres global com prod la jollagraham k coopercfo and treasurer san diegograham k coopercfo and treasurer la jollamichael a cowleychief scientific officer san diegomichael a cowleychief scientific officer la jollaendicott davidla jollawendy l dixondirector princetonassociates domainprincetondomain parters vii l p owner princetondomain partners v lp owner princetonbrian h doveydirector brian h doveydirector princetonbrian h doveydirector la jolladp v associates lp owner princetondp vii associates lp owner princetoneduardo dunayevichchief medical officer san diegoeduardo dunayevichchief medical officer la jollaweber eckardla jolladavid j endicottdirector irvinedavid j endicottdirector la jolla capeter d flynnsvp dev reg affairs safety san diegojoseph p haganchief business officer la jollabrian k halak owner princetonace heatherla jollapeter honigdirector la jolladebora jorndirector bridgewaterhagan josephla jollakim p kamdarprincetonjason a keyessvp chief financial officer la jolladennis d kimsr vp corporate development la jollaseth a klarmanbostonpreston klassenevp global development la jollakleiner perkins caufield  byers x a lp owner menlo parkkleiner perkins caufield  byers x b lp owner menlo parkkpcb x associates llc owner menlo parkjoseph lacobdirector san diegojoseph lacobdirector la jollajames c lancaster jrvp of commercial operations san diegoronald p landbloomvp medical and regulatory san diegoronald p landbloomvp medical and regulatory la jollazoth lotala jollabock louisla jollathomas p lynchevp general counsel  sec la jollam arkin  ltdherzliapatrick j mahaffydirector boulderpatrick j mahaffydirector la jollaanthony a mckinneychief operating officer san diegoanthony a mckinneychief business officer la jollanarachi michaella jollastephen a mogliavp chief accounting officer la jollaisrael mortel avivrobert j more owner princetonmichael narachiceo  president cambridgemichael narachipresident and ceo la jollamichael narachipresident and ceo la jollamahaffy patrickla jollahonig peterla jollawalter piskorskisvp technical operations la jollamichael powelldirector la jollamichael powelldirector san franciscomichael powelldirector menlo parkmichael powelldirector san diegoklassen prestonla jollasak corpbostonmichael c scaifela jollascale venture management ii llcfoster cityscale venture partners ii lp owner foster citykathleen k schoemaker owner princetonron senatortel avivsphera funds management ltdtel avivcannell thomasla jollalynch thomasla jollagary d tollefsonpresident and ceo san diegogary d tollefsonpresident and ceo la jollajesse i treu owner princetonjesse i treu owner princetondaniel k turner iiidirector la jolladaniel k turner iiidirector la jolladaniel k turner iiidirector san diegoheather d turnervice president san diegoheather d turnersvp gen counsel  secretary la jollanicole vitullo owner princetondawn viveashsvphead of regulatory affairs la jollaeckard weberdirector south san franciscoeckard weberdirector san diegoeckard weberdirector la jolladixon wendyla jollalota s zothdirector gaithersburglota s zothdirector la jolla potentially same personnamecitycountrysofinnova venture partners vi l pmenlo parkcasofinnova venture partners vi l pmenlo parkca active investments portfolio  sofinnova ventures home team portfolio about news contact healthquest capital sofinnova partners investor portal active investments selected realized investments remaining it investments active investments aclaris therapeutics specialty pharmaceutical dermatology company focused on the development of novel dermatologic therapies nasdaq acrs aerie pharmaceuticals clinicalstage biotechnology company dedicated to the discovery and development of novel treatments for glaucoma nasdaq aeri alimera sciences specializes in the research development and commercialization of prescription ophthalmic pharmaceuticals nasdaq alim amarin focused on improving the treatment of cardiovascular disease the company’s cardiovascular programs capitalize on its expertise in the field of lipid science and the known therapeutic benefits of essential fatty acids in treating cardiovascular disease nasdaq amrn anthera pharmaceuticals focused on developing and commercializing products to treat serious diseases associated with inflammation including cardiovascular and autoimmune diseases nasdaq anth antiva develop creatively designed therapeutics that dramatically improve health outcomes for patients suffering from diseases caused by hpv and other viruses ascendis pharma ascendis pharma develops differentiated prodrug versions of highvalue protein drugs such as growth hormone nasdaq asnd atyr pharma focused on the discovery and clinical development of innovative medicines for patients suffering from severe rare diseases using its knowledge of physiocrine biology a newly discovered set of physiological modulators nasdaq life audentes therapeutics committed to the development and commercialization of innovative new treatments for people with serious rare diseases through the application of gene therapy technology nasdaq bold auris medical prevention or treatment of inner ear disorders for acute inner ear tinnitus and for acute inner ear hearing loss nasdaq ears bioclin therapeutics our strategy is to develop biologics for medical conditions where there has been no approved or satisfactory therapy our lead product b is a human antibody targeting fgfr fibroblast growth factor receptor  being developed as a treatment for metastatic bladder cancer and achondroplasia dwarfism catalyst biosciences creating novel catalytic biopharmaceutical products based on engineered human proteases checkmate pharmacueticals developing novel approach to specifically activating the immune system to recognize and ultimately destroy tumor cells chiasma latestage biotech developing an oral drug candidate for acromegaly nasdaq chma coherus biosciences a leading developer of highquality therapeutics with a robust pipeline of biosimilar products nasdaq chrs dauntless pharmaceuticals biopharmaceutical company focused on the development of specialty drugs edge therapuetics develops commercialize novel hospitalbased therapies capable of transforming treatment paradigms in the management of acute lifethreatening neurological conditions nasdaq edge first aid shot therapy focused on the development and commercialization of a comprehensive portfolio of otc pharmaceutical products in liquid shot format galera therapeutics galera therapeutics is a private clinicalstage biotech company focused on the development of breakthrough drugs targeting the oxygen metabolic pathways histogenics combining cell therapy and tissue engineering technologies to develop highly innovative products for tissue repair and regeneration nasdaq hsgx hyperion therapeutics focused on the development of treatments that address critical unmet needs in the areas of gastroenterology and hepatology nadsaq hptx innocoll developing and manufacturing a range of pharmaceutical products and medical devices using its proprietary collagenbased technologies nasdaq innl merus clinicalstage immunooncology company developing innovative bispecific antibody therapeutics to treat and potentially cure cancer patients mirna therapeutics developing tumor suppressor micrornas mirnas to kill cancer cells by regaining control over multiple oncogenic pathways nasdaq mirn natera develops and commercializes noninvasive methods for analyzing dna nucana developing and commercialising novel anticancer medicines including next generation nucleotide prodrugs obseva dedicated to the development of innovative drugs for women’s reproductive medicine including preterm labor ocera focused on the development of drugs to treat a broad range of gastrointestinal and liver diseases nasdaq ocrx ophthotech corporation specializing in the development of novel therapeutics to treat diseases of the eye nasdaq opht principia biopharma focused on discovering and developing firstinclass small molecule drugs within the fields of autoimmune disease and oncology that are potent and safe prothena advancing and developing novel antibodies for broad range of diseases involving protein misfolding or cell adhesion including amyloidosis nasdaq prta spark therapeutics focused on developing curative onetime gene therapy products including lead gene therapy candidate for rperelated blindness nasdaq once versartis developing therapeutics for the treatment of endocrine disorders including human growth hormones nasdaq vsar ziarco ziarco is a private clinical stage biotechnology company developing products to treat chronic inflammatory diseases with a focus on inflammatory skin disorders in particular atopic dermatitis and psoriasis these diseases impact the wellbeing of millions of children and adults globally by severely reducing quality of life zs pharma focused on the treatment of kidney and liver diseases including hyperkalemia nasdaq zsph   sofinnova ventures inc active investments portfolio news june  art krieg comes down from the mountain with a m round for checkmate pharmaceuticals march  virtual biotech antiva sets out on a big rd quest armed with a m round for an hpv therapy march  bioclin therapeutics inc raises  million in series b financing led by sofinnova ventures and ysios capital january  obseva sa announces pricing of initial public offering january  obseva expands leadership team and board of directors with industry veterans december  novartis bolsters innovative dermatology portfolio through acquisition of ziarco group limited november  galera therapeutics receives m from sofinnova ventures november  galera therapeutics expands series b to  million july  dauntless takes flight with new business model for starting biotechs